EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Interchangeability of CSF and PET to identify Alzheimer's disease pathology

Samantha C Burnham iD, Anupa K Arora, Leonardo Iaccarino, Ian Kennedy, Vikas Kotari, Sameera R Wijayawardana, Leslie M Shaw, Natalya Benina, Ming Lu, Michael J Pontecorvo, Frances-Catherine Quevenco, Jian Wang and 1 more

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-04 · 18 (2)

DOI: 10.1002/dad2.70288 ↗

At a glance

Journal article in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, published online on 2026-05-12. Written by Samantha C Burnham and 12 co-authors. Institution: Eli Lilly and Company Indianapolis Indiana USA. 50 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIA NIH HHS, Eli Lilly and Company.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

INTRODUCTION Establishing interchangeability between cerebrospinal fluid (CSF) and positron emission tomography (PET) for patient identification may improve access to Alzheimer's disease (AD) therapies. METHODS Alzheimer's Disease Neuroimaging Initiative participants with mild cognitive impairment or AD dementia and available CSF, florbetapir PET, and/or flortaucipir PET were included. The interchangeability of CSF (per label threshold/method) and PET was evaluated for patient identification. RESULTS Fujirebio Lumipulse amyloid beta (Aβ) 42/Aβ40 ( N = 288) and Roche Elecsys phosphorylated tau 181 (P‐tau181)/Aβ42 ( N = 251) Conformité Européene (CE)‐marked CSF assays were in high agreement with and non‐inferior to florbetapir PET for identifying patients with AD pathology. High agreement was observed between Roche Elecsys CSF P‐tau181/Aβ42 ( N = 127) and an early (temporal) flortaucipir PET stratification. DISCUSSION CSF assays were interchangeable with amyloid PET to identify patients with AD pathology and were in high agreement with elevated early temporal flortaucipir PET. CSF biomarkers may be used as a robust alternative to PET, potentially increasing access to AD diagnosis and disease‐modifying treatments.

Subjects

Author keywords

AD pathologyAlzheimer's diseaseAlzheimer's disease diagnosisamyloid betabiomarkercerebrospinal fluid assaysconcordance analysispositron emission tomographytau

Authors and institutions

  • Eli Lilly and Company Indianapolis Indiana USA.
  • Eli Lilly and Company Sesto Fiorentino Italy.
  • Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA.
  • Fujirebio Diagnostics Inc. Malvern Pennsylvania USA.
  • Eli Lilly and Company Zurich Switzerland.

ORCID profiles: Samantha C Burnham

Funding

  • NIA NIH HHS
  • Eli Lilly and Company

Cite

APA

Burnham, S. C., Arora, A. K., Iaccarino, L., Kennedy, I., Kotari, V., Wijayawardana, S. R., Shaw, L. M., Benina, N., Lu, M., Pontecorvo, M. J., Quevenco, F. C., Wang, J., & Alzheimer's Disease Neuroimaging Initiative (2026). Interchangeability of CSF and PET to identify Alzheimer's disease pathology. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(2). https://doi.org/10.1002/dad2.70288

Vancouver

Burnham SC, Arora AK, Iaccarino L, Kennedy I, Kotari V, Wijayawardana SR, et al. Interchangeability of CSF and PET to identify Alzheimer's disease pathology. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(2). doi:10.1002/dad2.70288

BibTeX
@article{Burnham2026,
  author = {Burnham, Samantha C and Arora, Anupa K and Iaccarino, Leonardo and Kennedy, Ian and Kotari, Vikas and Wijayawardana, Sameera R and Shaw, Leslie M and Benina, Natalya and Lu, Ming and Pontecorvo, Michael J and Quevenco, Frances-Catherine and Wang, Jian and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
  title = {Interchangeability of CSF and PET to identify Alzheimer's disease pathology},
  journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
  year = {2026},
  volume = {18},
  number = {2},
  doi = {10.1002/dad2.70288}
}
Start for free →